Proactive Investors - Run By Investors For Investors

Orgenesis CEO talks through most recent collaborations: 3D cell printing and exosome technologies

Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan tells Proactive Investors the cell therapy development company has inked a collaboration and licensing deal with ExcellaBio Ltd for exosome-related technologies, in addition to a recent collaboration agreement with Digilab Inc to develop a live cell printing process and systems to automate the production of 3D cell and tissue structures.

 
View full ORGS profile View Profile

Orgenesis Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use